NASDAQ:GNTA Genenta Science (GNTA) Stock Price, News & Analysis → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Free GNTA Stock Alerts $2.55 -1.08 (-29.75%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$2.20▼$3.7050-Day Range$3.24▼$4.4952-Week Range$2.20▼$6.81Volume62,678 shsAverage Volume5,254 shsMarket Capitalization$46.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Genenta Science alerts: Email Address Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Genenta Science Stock (NASDAQ:GNTA)Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.Read More GNTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNTA Stock News HeadlinesApril 11, 2024 | cnn.comGenenta Science SpA Sponsored ADRMarch 4, 2024 | msn.comBioVie stock plunges 43% following public offering pricingApril 25, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...February 10, 2024 | markets.businessinsider.comBuy Rating for Genenta Science SpA on Strong Clinical Prospects and Innovative Gene Therapy PlatformFebruary 8, 2024 | finance.yahoo.comGenenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid TumorsFebruary 3, 2024 | finance.yahoo.comIs Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?November 14, 2023 | finance.yahoo.comIndividual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%August 18, 2023 | au.finance.yahoo.comGenenta Science S.p.A. (GNTA)April 25, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...July 28, 2023 | finance.yahoo.comGenenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor TreatmentsJuly 8, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn SituationJune 29, 2023 | finanznachrichten.deGENENTA SCIENCE SPA: The European Commission Grants Orphan Drug Designation to Temferon for Treatment of GliomaJune 29, 2023 | finance.yahoo.comThe European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of GliomaMay 17, 2023 | finance.yahoo.comInsiders own 30% of Genenta Science S.p.A. (NASDAQ:GNTA) shares but individual investors control 59% of the companyMay 16, 2023 | finance.yahoo.comGenenta to Provide Update on Lead Product Temferon™April 26, 2023 | finanznachrichten.deGENENTA SCIENCE SPA: Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F FilingApril 26, 2023 | finance.yahoo.comGenenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F FilingApril 3, 2023 | finance.yahoo.comGenenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor IndicationsMarch 2, 2023 | marketwatch.comGenenta Gets FDA Orphan-Drug Designation for Temferon in Glioblastoma Multiforme >GNTAMarch 2, 2023 | finance.yahoo.comFDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma MultiformeFebruary 24, 2023 | wsj.comGenenta Science S.p.A. ADRFebruary 8, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Genenta Science SpA Sponsored ADR (GNTA)February 7, 2023 | finance.yahoo.comGenenta Science and AGC Biologics Enter Development and Manufacturing Service AgreementJanuary 29, 2023 | finance.yahoo.comWe Think Genenta Science (NASDAQ:GNTA) Can Easily Afford To Drive Business GrowthDecember 8, 2022 | finance.yahoo.comGenenta Science S.p.A. (NASDAQ:GNTA) most popular amongst individual investors who own 60%, insiders hold 29%November 7, 2022 | finance.yahoo.comGenenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma PatientsOctober 24, 2022 | finance.yahoo.comGenenta Provides First Half 2022 Business Update and Financial ResultsSee More Headlines Receive GNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GNTA CUSIPN/A CIK1838716 Webwww.genenta.com Phone39-02-2643-4681FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio12.25 Quick Ratio12.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book2.11Miscellaneous Outstanding Shares18,220,000Free Float12,936,000Market Cap$46.46 million OptionableNot Optionable Beta0.72 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Pierluigi Paracchi (Age 51)Vice Chairman of the Board, CEO & GM Dr. Luigi Naldini M.D. (Age 65)Ph.D., Co-Founder & Chairman of the Executive Scientific Board Dr. Bernard Rudolph Gentner M.D. (Age 49)Ph.D., Co-Founder & Member of the Executive Scientific Board Mr. Richard B. Slansky (Age 66)Chief Financial Officer Dr. Carlo Russo M.D. (Age 71)Chief Medical Officer & Head of Development Dr. Stefania Mazzoleni Ph.D. (Age 42)Director of Program Development Ms. Barbara Regonini (Age 51)Director of Finance More ExecutivesKey CompetitorsIkena OncologyNASDAQ:IKNAEntera BioNASDAQ:ENTXInstil BioNASDAQ:TILElutiaNASDAQ:ELUTAligos TherapeuticsNASDAQ:ALGSView All Competitors GNTA Stock Analysis - Frequently Asked Questions Should I buy or sell Genenta Science stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genenta Science in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GNTA shares. View GNTA analyst ratings or view top-rated stocks. How have GNTA shares performed in 2024? Genenta Science's stock was trading at $4.95 at the beginning of the year. Since then, GNTA shares have decreased by 48.5% and is now trading at $2.55. View the best growth stocks for 2024 here. Are investors shorting Genenta Science? Genenta Science saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 3,000 shares, a drop of 9.1% from the March 15th total of 3,300 shares. Based on an average daily volume of 4,300 shares, the days-to-cover ratio is presently 0.7 days. View Genenta Science's Short Interest. When did Genenta Science IPO? Genenta Science (GNTA) raised $28 million in an IPO on Wednesday, December 15th 2021. The company issued 2,400,000 shares at $10.50-$12.50 per share. How do I buy shares of Genenta Science? Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GNTA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
